Opioid Use Disorder
Recent injection drug use linked to HCV reinfection after DAA treatment
WASHINGTON — The risk for hepatitis C virus reinfection after direct-acting antiviral therapy was high in people with recent injection drug use, while antipsychotic drugs and opioid agonists offered possible protective effects.
Video: Alternate word use recommended for specific terms involving opioid use
In this video, Karen Werder, PhD, PMHNP-BC, PHN, assistant professor at the Sonoma State University School of Nursing, discussed a presentation she gave at the American Psychiatric Nurses Association Annual Conference.
Video: Impact of language around opioid use disorder a key topic at APNA
In this video, Karen Werder, PhD, PMHNP-BC, PHN, assistant professor at the Sonoma State University School of Nursing, discussed a presentation she gave at the American Psychiatric Nurses Association Annual Conference.
FDA: Over-the-counter naloxone ‘may be approvable’
The FDA announced findings from a preliminary assessment that indicate certain naloxone products may be safely used without a prescription to prevent opioid overdose deaths.
Physicians overwhelmingly in favor of permanent telehealth use in OUD treatment
Physicians overwhelmingly favor making telehealth a permanent part of their practice for opioid use disorder treatment, according to a recent survey.
CDC updates clinical guidance on prescribing opioids for pain
The CDC has released updated and expanded clinical practice guidance on prescribing opioids to patients with short- and long-term pain.
Clinical evaluation of opioid use disorder treatment funded by $5.6M NIH grant
Biopharmaceutical company Aptinyx Inc. announced the finalization of a $5.6 million NIH grant for the development of a novel therapeutic for the treatment of opioid use disorder.
Data show a recent decline in opioid use, but disparities remain in LGBTQ+ community
Despite a downward trend in overall opioid use, disparities persist among members of the LGBTQ+ community, according to a study presented at the American Society of Anesthesiologists’ annual meeting.
Patients engaged in care for OUD more likely to continue care up to 24 months
The likelihood of retention over 6, 12 and 24 months was significantly higher for patients engaged in care for opioid use disorder, compared with those who were not, per a study published in the American Journal of Psychiatry.
Partnership promotes noninvasive therapeutic to treat opioid use disorder
Spark Biomedical has announced a partnership with AcuityMD to promote Spark’s noninvasive therapeutic to treat withdrawal symptoms associated with opioid use disorder.